236 related articles for article (PubMed ID: 37540514)
1. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
[TBL] [Abstract][Full Text] [Related]
2. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use.
Curtis M; Dietze P; Aitken C; Kirwan A; Kinner SA; Butler T; Stoové M
Harm Reduct J; 2018 Sep; 15(1):48. PubMed ID: 30241532
[TBL] [Abstract][Full Text] [Related]
3. Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.
Holmén E; Warnqvist A; Kåberg M
Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):24. PubMed ID: 37087485
[TBL] [Abstract][Full Text] [Related]
4. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply.
Tse WC; Djordjevic F; Borja V; Picco L; Lam T; Olsen A; Larney S; Dietze P; Nielsen S
Int J Drug Policy; 2022 Feb; 100():103513. PubMed ID: 34798434
[TBL] [Abstract][Full Text] [Related]
5. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
[TBL] [Abstract][Full Text] [Related]
6. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
[TBL] [Abstract][Full Text] [Related]
7. Risks and overdose responses: Participant characteristics from the first seven years of a national take-home naloxone program.
Ericson ØB; Eide D; Lobmaier P; Clausen T
Drug Alcohol Depend; 2022 Nov; 240():109645. PubMed ID: 36191532
[TBL] [Abstract][Full Text] [Related]
8. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
Holmén E; Hammarberg A; Kåberg M; Storbjörk J
Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
[TBL] [Abstract][Full Text] [Related]
9. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
[TBL] [Abstract][Full Text] [Related]
10. Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's perceptions of the BC take home naloxone program.
Mitchell K; Durante SE; Pellatt K; Richardson CG; Mathias S; Buxton JA
Harm Reduct J; 2017 Jun; 14(1):34. PubMed ID: 28592287
[TBL] [Abstract][Full Text] [Related]
11. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
Sajwani HS; Williams AV
Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
[TBL] [Abstract][Full Text] [Related]
13. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis.
McAuley A; Bouttell J; Barnsdale L; Mackay D; Lewsey J; Hunter C; Robinson M
Addiction; 2017 Feb; 112(2):301-308. PubMed ID: 27614084
[TBL] [Abstract][Full Text] [Related]
15. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities.
Dietze PM; Stare M; Cogger S; Nambiar D; Olsen A; Burns L; Lenton S
Drug Alcohol Rev; 2018 May; 37(4):457-463. PubMed ID: 29744979
[TBL] [Abstract][Full Text] [Related]
16. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?
Marino R; Landau A; Lynch M; Callaway C; Suffoletto B
Addiction; 2019 Sep; 114(9):1575-1581. PubMed ID: 31013394
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
[TBL] [Abstract][Full Text] [Related]
19. Who is using take-home naloxone? An examination of supersavers.
Eide D; Lobmaier P; Clausen T
Harm Reduct J; 2022 Jun; 19(1):65. PubMed ID: 35717240
[TBL] [Abstract][Full Text] [Related]
20. Take-home naloxone possession among people who inject drugs in rural West Virginia.
Allen ST; White RH; O'Rourke A; Grieb SM; Kilkenny ME; Sherman SG
Drug Alcohol Depend; 2019 Nov; 204():107581. PubMed ID: 31574407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
